Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • About
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Recurrent WHO Grade 2 Glioma”

29 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 29 results

Very early researchStudy completedNCT00874861
What this trial is testing

HLA-A2-Restricted Glioma Antigen-Peptides Vaccinations With Poly-ICLC for Recurrent WHO Grade II Gliomas

Who this might be right for
AstrocytomaOligoastrocytomaOligodendroglioma
Ian F. Pollack, M.D. 10
Large-scale testing (Phase 3)Active Not RecruitingNCT04576117
What this trial is testing

Compare Treatment With the Drug Selumetinib Alone Versus Selumetinib and Vinblastine in Patients With Recurrent or Progressive Low-Grade Glioma

Who this might be right for
Recurrent Low Grade AstrocytomaRecurrent WHO Grade 2 GliomaRefractory Low Grade Astrocytoma+2 more
National Cancer Institute (NCI) 300
Early research (Phase 1)Active Not RecruitingNCT06410248
What this trial is testing

Triapine in Combination With Temozolomide for the Treatment of Patients With Recurrent Glioblastoma

Who this might be right for
Recurrent Glioblastoma, IDH-WildtypeRecurrent WHO Grade 2 GliomaRecurrent WHO Grade 3 Glioma+1 more
Northwestern University 30
Testing effectiveness (Phase 2)Study completedNCT02986178
What this trial is testing

Lerapolturev in Recurrent Malignant Glioma

Who this might be right for
Malignant Glioma
Istari Oncology, Inc. 121
Testing effectiveness (Phase 2)Active Not RecruitingNCT03212274
What this trial is testing

Olaparib in Treating Patients With Advanced Glioma, Cholangiocarcinoma, or Solid Tumors With IDH1 or IDH2 Mutations

Who this might be right for
Advanced Malignant Solid NeoplasmGlioblastomaRecurrent Cholangiocarcinoma+4 more
National Cancer Institute (NCI) 89
Testing effectiveness (Phase 2)Active Not RecruitingNCT04195555
What this trial is testing

Ivosidenib in Treating Patients With Advanced Solid Tumors, Lymphoma, or Histiocytic Disorders With IDH1 Mutations (A Pediatric MATCH Treatment Trial)

Who this might be right for
Recurrent EpendymomaRecurrent Ewing SarcomaRecurrent Hepatoblastoma+30 more
National Cancer Institute (NCI) 3
Testing effectiveness (Phase 2)Study completedNCT00492089
What this trial is testing

Bevacizumab in Reducing CNS Side Effects in Patients Who Have Undergone Radiation Therapy to the Brain for Primary Brain Tumor, Meningioma, or Head and Neck Cancer

Who this might be right for
Adult Anaplastic AstrocytomaAdult Anaplastic EpendymomaAdult Anaplastic Meningioma+84 more
National Cancer Institute (NCI) 11
Early research (Phase 1)Ended earlyNCT01989052
What this trial is testing

Ph 1/2 CTO With Lomustine for Bevacizumab-Naive Recurrent Glioma

Who this might be right for
Malignant Glioma (WHO Grade III or IV)
Annick Desjardins 9
Testing effectiveness (Phase 2)Active Not RecruitingNCT04320888
What this trial is testing

Selpercatinib for the Treatment of Advanced Solid Tumors, Lymphomas, or Histiocytic Disorders With Activating RET Gene Alterations, a Pediatric MATCH Treatment Trial

Who this might be right for
Hematopoietic and Lymphatic System NeoplasmRecurrent EpendymomaRecurrent Ewing Sarcoma+35 more
National Cancer Institute (NCI) 1
Testing effectiveness (Phase 2)Looking for participantsNCT05765812
What this trial is testing

Debio 0123 in Combination With Temozolomide in Adult Participants With Recurrent or Progressive Glioblastoma and of Debio 0123 in Combination With Temozolomide and Radiotherapy in Adult Participants With Newly Diagnosed Glioblastoma

Who this might be right for
Glioblastoma IDH (Isocitrate Dehydrogenase) WildtypeAstrocytoma, Grade III
Debiopharm International SA 116
Testing effectiveness (Phase 2)Study completedNCT02343406
What this trial is testing

Adult Study: ABT-414 Alone or ABT-414 Plus Temozolomide vs. Lomustine or Temozolomide for Recurrent Glioblastoma Pediatric Study: Evaluation of ABT-414 in Children With High Grade Gliomas

Who this might be right for
Glioblastoma
AbbVie 266
Early research (Phase 1)Looking for participantsNCT04540107
What this trial is testing

Serial MR Imaging and MR Spectroscopic Imaging for the Characterization of Lower Grade Glioma

Who this might be right for
Recurrent World Health Organization (WHO) Grade II GliomaRecurrent WHO Grade III GliomaWHO Grade II Glioma+1 more
Susan Chang 300
Testing effectiveness (Phase 2)Study completedNCT03914742
What this trial is testing

BGB-290 and Temozolomide in Treating Patients With Recurrent Gliomas With IDH1/2 Mutations

Who this might be right for
IDH1 MutationIDH2 MutationRecurrent Glioblastoma+2 more
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins 67
Testing effectiveness (Phase 2)Study completedNCT04044937
What this trial is testing

Fluoroethyltyrosine for Evaluation of Intracranial Neoplasms

Who this might be right for
Intracranial NeoplasmLow Grade GliomaRecurrent Glioblastoma+2 more
Thomas Hope 143
Early research (Phase 1)Active Not RecruitingNCT04214392
What this trial is testing

Chimeric Antigen Receptor (CAR) T Cells With a Chlorotoxin Tumor-Targeting Domain for the Treatment of MMP2+ Recurrent or Progressive Glioblastoma

Who this might be right for
Recurrent GlioblastomaRecurrent Malignant GliomaRecurrent WHO Grade II Glioma+1 more
City of Hope Medical Center 19
Early research (Phase 1)Active Not RecruitingNCT03749187
What this trial is testing

BGB-290 and Temozolomide in Treating Isocitrate Dehydrogenase (IDH)1/2-Mutant Grade I-IV Gliomas

Who this might be right for
GlioblastomaIDH1 Gene MutationIDH2 Gene Mutation+7 more
University of California, San Francisco 78
Testing effectiveness (Phase 2)WithdrawnNCT05222165
What this trial is testing

Study With Infigratinib in Subjects With Advanced Solid and CNS Tumors or Recurrent or Progressive Low-Grade Glioma With Selected FGFR1-3 Alterations

Who this might be right for
Advanced Solid TumorCNS TumorRecurrent WHO Grade II Glioma
Helsinn Healthcare SA
Very early researchStudy completedNCT01678352
What this trial is testing

Imiquimod and Tumor Lysate Vaccine Immunotherapy in Adults With High Risk or Recurrent Grade II Gliomas

Who this might be right for
High Risk WHO Grade II GliomaRecurrent/Post-Chemotherapy WHO Grade II Glioma
Frank Lieberman 19
Testing effectiveness (Phase 2)Study completedNCT01817751
What this trial is testing

Sorafenib, Valproic Acid, and Sildenafil in Treating Patients With Recurrent High-Grade Glioma

Who this might be right for
GlioblastomaRecurrent Adult Brain NeoplasmMalignant Glioma+1 more
Virginia Commonwealth University 47
Testing effectiveness (Phase 2)Active Not RecruitingNCT04284774
What this trial is testing

Tipifarnib for the Treatment of Advanced Solid Tumors, Lymphoma, or Histiocytic Disorders With HRAS Gene Alterations, a Pediatric MATCH Treatment Trial

Who this might be right for
Malignant Solid NeoplasmRecurrent Adrenal Gland PheochromocytomaRecurrent Ectomesenchymoma+38 more
National Cancer Institute (NCI) 5
Load More Results